FDA Approved: DYANAVEL XR — Original Application (NextWave Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved DYANAVEL XR (amphetamine extended-release) from NextWave Pharmaceuticals as a new treatment for attention-deficit/hyperactivity disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dyanavel XR (amphetamine (extended-release))

Snippet

ORIG AP for DYANAVEL XR (AMPHETAMINE)